Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03343197 · ClinicalTrials.gov registry record · Phase 1

Study of AG-120 and AG-881 in Subjects With Low Grade Glioma

A Phase 1 study, sponsored by Institut de Recherches Internationales Servier.

Completed
Registry status
Phase 1
Development phase
49
Enrollment target

NCT03343197: Completed Phase 1 study, sponsored by Institut de Recherches Internationales Servier.

NCT03343197 is a Phase 1 study that has completed, run by Institut de Recherches Internationales Servier. The registered enrollment target is 49 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (18% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03343197, a Phase 1 study, has completed, sponsored by Institut de Recherches Internationales Servier.

COMPLETED
Registry status
Phase 1
Development phase
49 participants
Enrollment target

Study Summary

Study to evaluate the suppression of 2-HG (2-hydroxyglutarate) in IDH-1 mutant gliomas in resected tumor tissue following pre-surgical treatment with AG-120 or AG-881.

Interventions

  • DRUG AG-120
  • DRUG AG881

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 2018-03-20
Est. Completion 2025-03-28
Phase Phase 1

What the finished NCT03343197 record still lists

NCT03343197 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (18% lower).

The record links to 0 conditions, and to 2 interventions - of which AG-120 is the first listed.

NCT03343197 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03343197 about?

NCT03343197 is a clinical study titled "Study of AG-120 and AG-881 in Subjects With Low Grade Glioma". Study to evaluate the suppression of 2-HG (2-hydroxyglutarate) in IDH-1 mutant gliomas in resected tumor tissue following pre-surgical treatment with AG-120 or AG-881.

What is the current status of trial NCT03343197?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 49 participants. The study started on 2018-03-20. Estimated completion is 2025-03-28.

What interventions are being tested in trial NCT03343197?

The interventions under investigation include: AG-120 (DRUG), AG881 (DRUG).

Who is sponsoring clinical trial NCT03343197?

This trial is sponsored by Institut de Recherches Internationales Servier, which has 27 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03343197's enrollment target sits among peer trials

49 1017th of 2000 higher than 976 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02704858 · 49 participants · Phase 1

    Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

  • NCT03516708 · 49 participants · Phase 1

    Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

  • NCT03692429 · 49 participants · Phase 1

    alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

  • NCT04329494 · 49 participants · Phase 1

    PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03343197, the US trial registry maintained by the National Library of Medicine. NCT03343197 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.